Clinical prostate cancer最新文献

{"title":"Second-Line Chemotherapy for Prostate Cancer: Patient Characteristics and Survival","authors":"Kathleen W. Beekman ,&nbsp;Mark T. Fleming ,&nbsp;Howard I. Scher ,&nbsp;Susan F. Slovin ,&nbsp;Nicole M. Ishill ,&nbsp;Glenn Heller ,&nbsp;W. Kevin Kelly","doi":"10.3816/CGC.2005.n.015","DOIUrl":"10.3816/CGC.2005.n.015","url":null,"abstract":"<div><h3>Purpose</h3><p>First-line chemotherapy with docetaxel in patients with progressive castrate metastatic prostate cancer has been shown to improve overall survival compared with mitoxantrone-based therapies. The use and outcomes of chemotherapy after first-line antimicrotubule-based therapy have not been well described.</p></div><div><h3>Patients and Methods</h3><p>Patients with progressive castrate metastatic prostate cancer enrolled on an antimicrotubule-based protocol for treatment were followed to determine their baseline characteristics and outcomes with second- or third-line systemic therapy.</p></div><div><h3>Results</h3><p>Of 108 patients treated with antimicrotubulebased therapy, 81% received second-line therapy, and 40% received third-line therapies. Corresponding prostate-specific antigen (PSA) decreases ≥ 50% were observed in 72%, 15%, and 22% of patients. Median survival times from the start of first-, second-, and third-line therapy were 21 months (95% confidence interval [CI], 18-25 months), 13 months (95% CI, 10-15 months) and 12 months (95% CI, 9-19 months). Significant prognostic indicators for survival in the second-line setting include pretreatment PSA level, alkaline phosphatase level, and performance status. Patients not fit to receive second-line therapy were more symptomatic with first-line therapy, as illustrated by a greater need for narcotic therapy (67% vs. 15%) and palliative radiation therapy after first-line therapy (57% vs. 10%) in lieu of second-line systemic therapy.</p></div><div><h3>Conclusion</h3><p>Eighty percent of patients received second-line chemotherapy, with a median survival of 12 months from the start of second-line treatment. Although only 40% received third-line chemotherapy, median survival was similar to that of patients in the second-line setting. Our data show that patients who initiate chemotherapy with symptoms are more likely to require palliative radiation therapy rather than chemotherapy as second-line therapy. A sequential or continuous administration of therapy may optimize the care of this subset of symptomatic patients.</p></div>","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Pages 86-90"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CGC.2005.n.015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25633307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate-Specific Membrane Antigen Vaccines: Naked DNA and Protein Approaches","authors":"Susan F. Slovin","doi":"10.3816/CGC.2005.n.020","DOIUrl":"10.3816/CGC.2005.n.020","url":null,"abstract":"<div><p>Prostate-specific membrane antigen (PSMA) is a relatively omnipresent molecule with a multiplicity of functions and has been shown to be a reasonable target for immunologic approaches such as vaccines or more directed therapy with radioactively labeled monoclonal antibodies against PSMA. Given the abundance of various glycoprotein and carbohydrate antigens expressed on the surface of prostate cancer cells and cell lines, PSMA stands out as another self-antigen that is not only expressed on cancer cells but also on neovasculature. Although vaccines are varied in their design and target goal, recent technology has afforded researchers the opportunity to induce recruitment of multiple effector cell populations, cytokines, and factors that can elicit cellular and humoral responses. This review serves to present unique approaches in vaccine development that can induce immunologic responsiveness to PSMA with potential impact on disease progression.</p></div>","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Pages 118-123"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CGC.2005.n.020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25624836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Clinical Data and Potential Clinical Utility of Novel Histone Deacetylase Inhibitors in Prostate Cancer","authors":"G. Kesava Reddy PhD,&nbsp;Eric Nadler MD,&nbsp;Arif Hussain MD","doi":"10.1016/S1540-0352(11)70115-9","DOIUrl":"10.1016/S1540-0352(11)70115-9","url":null,"abstract":"","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Pages 83-85"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1540-0352(11)70115-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25633306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer","authors":"Elisabeth I. Heath ,&nbsp;Melvin Gaskins ,&nbsp;Henry C. Pitot ,&nbsp;Roberto Pili ,&nbsp;Winston Tan ,&nbsp;Robert Marschke ,&nbsp;Glenn Liu ,&nbsp;David Hillman ,&nbsp;Fazlul Sarkar ,&nbsp;Shijie Sheng ,&nbsp;Charles Erlichman ,&nbsp;Percy Ivy","doi":"10.3816/CGC.2005.n.024","DOIUrl":"10.3816/CGC.2005.n.024","url":null,"abstract":"","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Pages 138-141"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CGC.2005.n.024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25624840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights from the 5th Annual International Congress on Monoclonal Antibodies in Cancer Quebec City, Canada, August 2005 5th International Prostate Cancer Congress Rio Grande, Puerto Rico, July 2005 41st Annual Meeting of the American Society of Clinical Oncology Orlando, Florida, May 2005","authors":"G. Kesava Reddy PhD,&nbsp;Preeta Tyagi PhD,&nbsp;Eric Nadler MD,&nbsp;Vinay K. Jain MD","doi":"10.1016/S1540-0352(11)70108-1","DOIUrl":"10.1016/S1540-0352(11)70108-1","url":null,"abstract":"","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Pages 73-78"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1540-0352(11)70108-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25633304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orbital Metastasis from Prostate Cancer: An Atypical Case of Neuroendocrine Dedifferentiation During Progression from Hormone-Sensitive to Refractory Stage","authors":"Suneetha Challagundla ,&nbsp;Murat Gokden ,&nbsp;Sanjaya Viswamitra ,&nbsp;Manish Kohli","doi":"10.3816/CGC.2005.n.023","DOIUrl":"10.3816/CGC.2005.n.023","url":null,"abstract":"<div><p>We report a case of orbital metastasis from a neuroendocrine dedifferentiated prostate cancer during progression from hormone-sensitive to hormone refractory stage. A patient receiving androgen deprivation for hormone-sensitive prostate cancer presented with sudden-onset rightsided ptosis and an increasing serum prostate-specific antigen level. Imaging studies revealed a mixed blastic and lytic lesion involving the right orbital wall and the right cavernous sinus. Comparison of the metastatic histology with the original pathology confirmed a histologic change to poorly differentiated prostate adenocarcinoma with neuroendocrine features. Local radiation of the lesion and palliative systemic chemotherapy resulted in marked short-term improvement of all presenting symptoms. Because prostate cancer metastasis involves hematogenous and lymphatic routes, we also evaluated expression of the vascular endothelial growth factor (VEGF) and receptors (VEGFR-1, VEGFR-2, and VEGFR-3) in the metastatic deposit by immunohistochemistry. Strong expression of VEGFR-2 and VEGFR-3 restricted to the malignant epithelium was noted. We recommend a second biopsy of atypical prostate metastasis associated with sudden change to aggressive clinical behavior in order to evaluate for dedifferentiation features before planning appropriate treatment interventions especially in patients who are candidates for systemic chemotherapy.</p></div>","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Pages 134-137"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CGC.2005.n.023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25624839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selected Clinical Trials In Prostate Cancer","authors":"","doi":"10.1016/S1540-0352(11)70104-4","DOIUrl":"https://doi.org/10.1016/S1540-0352(11)70104-4","url":null,"abstract":"","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Page 142"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1540-0352(11)70104-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136554294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Role of Inhibiting the Vascular Endothelial Growth Factor Pathway in Advanced Prostate Cancer","authors":"Preeta Tyagi PhD,&nbsp;Eric Nadler MD,&nbsp;Arif Hussain MD","doi":"10.1016/S1540-0352(11)70112-3","DOIUrl":"10.1016/S1540-0352(11)70112-3","url":null,"abstract":"","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Pages 80-82"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1540-0352(11)70112-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25633305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative Computed Tomography Perfusion of Prostate Cancer: Correlation with Whole-Mount Pathology","authors":"Elizabeth P. Ives ,&nbsp;Melissa A. Burke ,&nbsp;Pamela R. Edmonds ,&nbsp;Leonard G. Gomella ,&nbsp;Ethan J. Halpern","doi":"10.3816/CGC.2005.n.018","DOIUrl":"10.3816/CGC.2005.n.018","url":null,"abstract":"<div><h3>Purpose</h3><p>Microvessel density within the prostate is associated with presence of cancer, disease stage, and disease-specific survival. We evaluated multidetector computed tomography (CT) to estimate prostate perfusion and localize prostate cancer.</p></div><div><h3>Patients and Methods</h3><p>Ten subjects were evaluated with contrast enhanced CT before radical prostatectomy with the Mx8000IDT 16-slice scanner. Following baseline pelvic scan, 100 cc of Optiray® 300 was administered intravenously (4 cc per second). Repeated dynamic scans through the prostate were obtained at 20, 30, 40, 50, and 60 seconds following initiation of contrast injection. Computed tomography perfusion was compared with pathologic findings of Gleason score and tumor volume on whole-mount prostatectomy specimens.</p></div><div><h3>Results</h3><p>Conventional adenocarcinoma (Gleason score, 6-10) was present in all subjects, including one who also demonstrated a mucinous variant of prostate cancer. Visible focal CT enhancement was noted in 1 patient with a high-volume tumor and a Gleason score of 10. A positive correlation between local estimates of CT perfusion and percent of prostate volume occupied by tumor in each sextant was found for half of the subjects (Pearson correlation coefficient, 0.3-0.95; mean, 0.48) but statistically significant correlation (<em>P</em> &lt; 0.05; Pearson coefficient, 0.9- 0.95) was present in only the 2 subjects with the highest Gleason scores (8 and 10) and the highest tumor volume (≥ 50% in ≥ 1 sextant region).</p></div><div><h3>Conclusion</h3><p>Visible enhancement of prostate cancer during dynamic CT is present in a minority of subjects. Correlation between quantitative CT perfusion and tumor location is statistically significant only in subjects with localized high-volume, poorly differentiated prostate cancer.</p></div>","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Pages 109-112"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CGC.2005.n.018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25633829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prior Estrogen Therapy as a Predictor of Response to Subsequent Estramustine-Based Chemotherapy in Patients with Androgen-Independent Prostate Cancer","authors":"Jorge A. Garcia ,&nbsp;Vivian Weinberg ,&nbsp;Eric J. Small","doi":"10.3816/CGC.2005.n.019","DOIUrl":"10.3816/CGC.2005.n.019","url":null,"abstract":"<div><h3>Background</h3><p>Hormone-refractory prostate cancer (HRPC) has modest response rates to second-line estrogenic agents such as diethylstilbestrol and the herbal product PC SPES. Estramustine phosphate (EMP) is a microtubule inhibitory agent with estrogenic properties commonly used in patients with metastatic HRPC. To determine whether previous response to second-line estrogen therapy would predict subsequent response to EMP-based chemotherapy, a retrospective study was conducted.</p></div><div><h3>Patients and Methods</h3><p>Patients with HRPC previously treated with second-line estrogenic therapy who subsequently received EMPbased chemotherapy were enrolled in a retrospective analysis. The progression of disease or response to treatment was determined with use of standard prostate-specific antigen (PSA) criteria and Response Evaluation Criteria in Solid Tumors.</p></div><div><h3>Results</h3><p>Seventy-eight patients were included in the analysis. Twenty-five patients with disease progression after receiving estrogen therapy received subsequent EMP-based chemotherapy. Overall, initial PSA response to any estrogen therapy was 54%. The overall PSA response to EMP-based chemotherapy was 60%, and the objective response was 36%. The PSA response to subsequent EMP-based chemotherapy was independent of patients having a previous response to estrogen therapy (70% vs. 53%; <em>P</em> = 0.68). The median overall survival for patients receiving estrogenic therapy and subsequent EMPbased chemotherapy was 12.7 months.</p></div><div><h3>Conclusion</h3><p>Previous response to second-line hormonal maneuvers with estrogen therapy does not predict subsequent response to EMP-based chemotherapy.</p></div>","PeriodicalId":87076,"journal":{"name":"Clinical prostate cancer","volume":"4 2","pages":"Pages 113-117"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CGC.2005.n.019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25633830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}